CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
LEE011 +1 moredrug
Likely dose
Everolimus 2.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02985125
NCT02985125Phase 2Completed
CompareCT.gov

A Phase I/II Study of LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

Georgetown University·interventional·Posted Dec 7, 2016·Updated Apr 7, 2026

In Brief

A Phase 2 clinical trial evaluating LEE011 and Everolimus for Metastatic Pancreatic Adenocarcinoma. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This study is a single-arm, open-label, multi-institutional Phase I/II trial of the combination of LEE011 and everolimus in refractory mPAC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Adenocarcinoma
CountriesUnited States
CollaboratorsNovartis, University of Texas Southwestern Medical Center, Cedars-Sinai Medical Center, Virginia Mason Hospital/Medical Center

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 7, 2016
Enrollment StartMay 4, 2017
Primary CompletionJul 24, 2019
Study CompletionSep 28, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.6 years ago

Interventions

LEE011drug

Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.

Everolimusdrug

Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.